<DOC>
	<DOCNO>NCT01708174</DOCNO>
	<brief_summary>This Phase II study evaluate safety efficacy LDE225 adult pediatric patient Hh-pathway activate , relapse MB .</brief_summary>
	<brief_title>A Phase II Study Oral LDE225 Patients With Hedge-Hog ( Hh ) -Pathway Activated Relapsed Medulloblastoma ( MB )</brief_title>
	<detailed_description />
	<mesh_term>Medulloblastoma</mesh_term>
	<criteria>Patients histologically confirm diagnosis MB , experience relapse progression standardofcare therapy include radiotherapy . Patients currently receive steroid must stable ( decrease ) dose least 5 day initiate study therapy . Only patient test result , use 5gene Hh signature assay , indicate Hhpathway activate MB eligible study . All available tumor material obtain time course patient 's disease submit analysis At least one measurable lesion define lesion ( ) accurately measure least two dimension ≥ 10 mm dimension Gadolinium ( Gd ) MRI , irrespective slice thickness/reconstruction interval , CNS lesion CT MRI ( without contrast ) nonCNS lesion . All patient CNS lesion must brain MRI without gadolinium spine MRI gadolinium within 2 week prior first dose study treatment . Performance Status correspond ECOG score 0 , 1 , 2 : 1 . Karnofsky performance status score ≥ 50 patient &gt; 16 year age 2 . Lansky performance status score ≥ 50 patient ≤ 16 year age Adequate bone marrow function define : 1 . Peripheral absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L 2 . Platelet count ≥ 80 x 109/L 3 . Hemoglobin ( Hgb ) ≥ 9 g/dL Serum CK ≤1.5 ULN Prior treatment Smoothened inhibitor Systemic anticancer treatment within 2 week first dose study treatment ( 6 week nitrosourea , mitomycin , monoclonal antibody ) . Focal radiation therapy within 4 week first dose study treatment , full spinal radiotherapy within 3 month first dose study treatment . Patients neuromuscular disorder associate elevated CK ( eg , inflammatory myopathy , muscular dystrophy , amyotrophic lateral sclerosis , spinal muscular atrophy ) . Patients receive treatment medication know strong inhibitor inducer CYP3A4/5 metabolize CYP2B6 CYP2C9 , narrow therapeutic index discontinue least 2 week first dose study treatment duration study Patients receive unstable increase dos corticosteroid . If patient corticosteroids endocrine deficiency tumorassociated symptom , dose must stabilize ( decrease ) least 5 day first dose study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>4 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>medulloblastoma ,</keyword>
	<keyword>relapse ,</keyword>
	<keyword>pediatric ,</keyword>
	<keyword>child ,</keyword>
	<keyword>adult ,</keyword>
	<keyword>Hh pathway inhibitor ,</keyword>
	<keyword>LDE225</keyword>
</DOC>